ORLADEYO
Total Payments
$3.7M
Transactions
16,666
Doctors
3,367
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $477,288 | 6,269 | 2,009 |
| 2023 | $735,520 | 5,799 | 1,981 |
| 2022 | $2.5M | 4,598 | 1,673 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 44 | 48.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 366 | 27.4% |
| Food and Beverage | $411,415 | 15,742 | 11.0% |
| Travel and Lodging | $188,702 | 416 | 5.1% |
| Consulting Fee | $159,729 | 78 | 4.3% |
| Grant | $108,083 | 3 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $12,600 | 7 | 0.3% |
| Education | $6,896 | 10 | 0.2% |
Payments by Type
General
$1.9M
16,622 transactions
Research
$1.8M
44 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Randomized Double-Blind, Placebo-Controlled QT/QTc Study To Evaluate The Effects That Extra Doses of Berotralstat Administered At Steady State Have On Cardiac Repolarization in Healthy Subjects | BioCryst Pharmaceuticals, Inc. | $1.4M | 0 |
| A Phase 1 Study drug interaction study to evaluate the effect of cyclosporine on the pharmacokinetics of berotralstat in healthy subjects | BioCryst Pharmaceuticals, Inc. | $293,619 | 0 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema | BioCryst Pharmaceuticals, Inc. | $63,728 | 0 |
| An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema | BioCryst Pharmaceuticals, Inc. | $34,253 | 0 |
| A Phase 1 Drug Interaction Study to Evaluate the Effects of BCX7353 on the Pharmacokinetics of Two Oral Contraceptives Desogesterel and Combo CC | BioCryst Pharmaceuticals, Inc. | $15,895 | 0 |
Top Doctors Receiving Payments for ORLADEYO — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Allergy & Immunology | Seattle, WA | $20,961 | 33 |
| , PA-C | Medical | Dallas, TX | $17,378 | 75 |
| , M.D | Allergy & Immunology | Gardner, KS | $15,781 | 46 |
| , M.D | Allergy & Immunology | San Antonio, TX | $12,731 | 26 |
| , MD | Allergy & Immunology | Saint Louis, MO | $11,987 | 21 |
| , MD | Allergy & Immunology | Middletown, RI | $8,871 | 23 |
| , MD | Internal Medicine | Cincinnati, OH | $8,727 | 21 |
| , FNP-C | Allergy & Immunology | Scottsdale, AZ | $8,277 | 37 |
| , DO | Allergy & Immunology | Northampton, MA | $6,434 | 32 |
| , M.D | Internal Medicine | Layton, UT | $6,147 | 23 |
| , PHD, DNP, RN, FNP-BC | Family | Wilmington, DE | $5,838 | 25 |
| , MD | Internal Medicine | Charlestown, MA | $5,266 | 4 |
| , M.D | Allergy & Immunology | Plainview, NY | $5,128 | 36 |
| , DO | Allergy & Immunology | Hershey, PA | $4,845 | 19 |
| , MD, PHD | Allergy & Immunology | Skyland, NC | $4,842 | 34 |
| , MD | Internal Medicine | Ann Arbor, MI | $3,232 | 6 |
| , MD | Internal Medicine | Jacksonville, FL | $2,876 | 47 |
| , M.D | Allergy & Immunology | Normal, IL | $2,815 | 4 |
| , MD | Allergy & Immunology | Sandy Springs, GA | $2,627 | 20 |
| , MD | Allergy & Immunology | Durham, NC | $2,157 | 3 |
| , MD-PHD | Allergy & Immunology | Forest Hills, NY | $2,034 | 50 |
| , MD | Allergy & Immunology | Altamonte Springs, FL | $1,766 | 81 |
| , MD | Allergy & Immunology | La Jolla, CA | $1,685 | 2 |
| , MD | Allergy & Immunology | New York, NY | $1,650 | 1 |
| , MD | Allergy & Immunology | Washington, DC | $1,472 | 16 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.7M
- Total Doctors 3,367
- Transactions 16,666
About ORLADEYO
ORLADEYO is a drug associated with $3.7M in payments to 3,367 healthcare providers, recorded across 16,666 transactions in the CMS Open Payments database. The primary manufacturer is BioCryst Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $477,288 was paid across 6,269 transactions to 2,009 doctors.
The most common payment nature for ORLADEYO is "Unspecified" ($1.8M, 48.7% of total).
ORLADEYO is associated with 5 research studies, including "A Phase 1, Randomized Double-Blind, Placebo-Controlled QT/QTc Study To Evaluate The Effects That Extra Doses of Berotralstat Administered At Steady State Have On Cardiac Repolarization in Healthy Subjects" ($1.4M).